Where there is hope: a qualitative study examining patients’ adherence to multi-drug resistant tuberculosis treatment in Karakalpakstan, Uzbekistan by unknown
RESEARCH ARTICLE Open Access
Where there is hope: a qualitative study
examining patients’ adherence to multi-
drug resistant tuberculosis treatment in
Karakalpakstan, Uzbekistan
Shona Horter1*, Beverley Stringer1, Jane Greig1, Akhmet Amangeldiev2, Mirzagaleb N. Tillashaikhov3,
Nargiza Parpieva3, Zinaida Tigay4 and Philipp du Cros1
Abstract
Background: Treatment for multi-drug resistant tuberculosis (MDR-TB) is lengthy, has severe side effects, and
raises adherence challenges. In the Médecins Sans Frontières (MSF) and Ministry of Health (MoH) programme
in Karakalpakstan, Uzbekistan, a region with a high burden of MDR-TB, patient loss from treatment (LFT)
remains high despite adherence support strategies. While certain factors associated with LFT have been
identified, there is limited understanding of why some patients are able to adhere to treatment while others
are not. We conducted a qualitative study to explore patients’ experiences with MDR-TB treatment, with the
aim of providing insight into the barriers and enablers to treatment-taking to inform future strategies of
adherence support.
Methods: Participants were purposively selected. Programme data were analysed to enable stratification of
patients by adherence category, gender, and age. 52 in-depth interviews were conducted with MDR-TB
patients (n = 35) and health practitioners (n = 12; MSF and MoH doctors, nurses, and counsellors), including
five follow-up interviews. Interview notes, then transcripts, were analysed using coding to identify emerging
patterns and themes. Manual analysis drew upon principles of grounded theory with constant comparison of
codes and categories within and between cases to actively seek discrepancies and generate concepts from
participant accounts. Ethics approval was received from the MoH of the Republic of Uzbekistan Ethics
Committee and MSF Ethics Review Board.
Results: Several factors influenced adherence. Hope and high quality knowledge supported adherence;
autonomy and control enabled optimal engagement with treatment-taking; and perceptions of the body, self,
treatment, and disease influenced drug tolerance. As far as we are aware, the influence of patient autonomy
and control on MDR-TB treatment-taking has not previously been described. In particular, the autonomy of
married women around treatment-taking was potentially undermined through their societal position as
daughter-in-law, compromising their ability to adhere to treatment. Patients’ engagement with and adherence
to treatment could be hindered by hierarchical practitioner-patient relationships that displaced authority,
ownership, and responsibility from the patient.
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Conclusions: Our findings reinforce the need for an individualised and holistic approach to adherence
support with engagement of patients as active participants in their care who feel ownership and
responsibility for their treatment.
Keywords: MDR-TB, Multi-drug resistant tuberculosis, Adherence, Qualitative study, Drugs, Autonomy, Side
effects
Background
In 2013, approximately 480,000 people globally devel-
oped multi-drug resistant tuberculosis (MDR-TB),
defined as TB resistant to rifampicin and isoniazid [1].
Treatment for MDR-TB is lengthy, has low efficacy,
often causes severe side effects, and raises adherence
challenges [2]. Adherence to medical treatment is a
complex behavioural issue, influenced by many factors
that are often context specific [3]. In MDR-TB treat-
ment, poor adherence can have medical and public
health implications [4–7].
A meta-analysis of MDR-TB treatment studies across
31 countries found a pooled proportion of patients lost
from treatment (LFT; patients whose treatment is inter-
rupted for at least two consecutive months) of 14.8 %.
Strategies associated with reduced LFT include engage-
ment of community health workers in administering and
observing treatment, smaller cohort sizes through
decentralised care, patient education, and a package of
adherence interventions such as nutrition and financial
support [5]. It is possible that some patients classified as
LFT are actually treatment failures [8, 9]. The most fre-
quently cited factor associated with LFT is alcohol use
[4, 5, 7, 8, 10–13], others being a history of imprison-
ment [6, 8, 12], more severe drug resistance [8, 14], and
socio-demographic factors including homelessness and
lower education levels [12, 14]. Some data are contra-
dictory, for example both employment and unemploy-
ment have been associated with LFT [7, 12], as have the
intensive and continuation phases of treatment [15, 16].
Side effects, fear that treatment is ineffective or harmful,
and perceptions around ill-health and cure can also lead
to patients not completing treatment [8].
Uzbekistan is one of the high priority countries for
drug-resistant TB in the European region, with 23 %
MDR TB amongst new TB cases [1]. In Karakalpakstan,
an autonomous region in the northwest of the country,
proportions of MDR-TB were over 40 % of new and over
75 % of previously treated cases in 2010–2011 [17],
which indicated the presence of primary transmission as
well as resistance amplification. Médecins Sans Fron-
tières (MSF) and the Ministry of Health (MoH) operate
a TB programme in accordance with international guide-
lines in Karakalpakstan, where the model of treatment
and care is decentralised, and ambulatory from day one
[18]. Daily MDR-TB treatment is administered directly
observed (directly observed treatment; DOT) at “DOT
corners” within ambulatory health facilities, or at patient
homes for certain patients with challenges accessing
their nearest health facility.
Among patients starting treatment for MDR-TB
between 2009 and 2012 (n = 1,190), 57 % had a success-
ful treatment outcome, 27 % were LFT, 9 % died, and
7 % failed treatment. Adherence support strategies in
the programme include: individual pre-treatment assess-
ment by counsellors to provide information and assess
readiness for starting treatment; one-to-one counselling
or psychiatric support if needed; engagement of family
members and family information sessions (with patient
consent); peer support group meetings; and social sup-
port. In addition, health practitioners receive training
sessions on adherence and communication. However,
rates of LFT from MDR-TB treatment remain high.
While certain factors associated with LFT have been
identified, there is limited understanding of why these
factors interfere with completion of treatment, and why
some patients are able to adhere to treatment while
others are not. We therefore conducted a qualitative
study to determine the reasons for adherence and non-
adherence in MDR-TB patients in Karakalpakstan,
Uzbekistan. Our aim was to provide insight into the pat-
terns of patients’ adherence, exploring the barriers and
enablers to treatment-taking in order to inform future
strategies of adherence support.
Methods
A qualitative study design was adopted in order to
examine patient experiences with MDR-TB and
treatment-taking, including the challenges and support-
ive factors, from their perspectives, as well as from the
perspective of health practitioners. This study was con-
ducted towards the end of 2014 and included in-depth
interviews with MDR-TB patients and health
practitioners.
Sampling criteria
Patient participants were identified via purposive sampling
in order to recruit those best able to provide insight into
adherence to MDR-TB treatment, and to achieve max-
imum variation in treatment-taking experiences. Health
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practitioner participants were also included in order to
explore their experiences working with MDR-TB patients
and their views and observations regarding the barriers
patients face and enablers that help them overcome chal-
lenges. In addition, inclusion of health practitioners was
intended to allow further depth of insight into the
treatment-taking process and staff-patient relationships.
Follow-up interviews were conducted with selected
participants to enable interpretive theories generated
from emerging data to be further examined [19]. Partici-
pants for follow-up interview were identified through
reviewing interview transcripts and considering areas
where depth of insight could be expanded.
Sampling frame
Patients’ treatment-taking information was obtained
from the project database, which included health practi-
tioner DOT records of doses prescribed versus those
observed as being taken (for example, where patients do
not present to the clinic for daily observed treatment, or
refuse certain drugs). Patients were stratified by adher-
ence into three categories: adhered well (observed taking
over 90 % of treatment as prescribed); partially adhered
(observed taking up to 50 % of treatment as prescribed);
and LFT within the preceding 6 months. Sample recruit-
ment was also stratified for patient characteristics, in-
cluding gender and age. Health practitioners were
identified to include MSF and MoH practitioners in a
range of professions including doctors, nurses, and coun-
sellors, who all had experience supporting and/or treating
patients with MDR-TB.
Participant recruitment
Patient participants were contacted by members of the
psychosocial team with information about the study ask-
ing whether they would be willing to be interviewed. In-
terviews were arranged with those who agreed to take
part at a time and location convenient for them, which
was either at their home or in a private room at the
DOT corner (outpatient TB department). Health practi-
tioners were given information about the study by the
principal investigator and asked if they would be willing
to take part, with interviews then held in a private room
of the project office or DOT corner.
Data collection
In-depth interviews were conducted from September to
November 2014. All interviews (n = 52) were carried out
by the principal investigator, the majority in the local
language (Karakalpak) with a trained interpreter, or in
English. Interviews were participant-led and encouraged
natural flow of conversation, based on topic guides to
explore specific areas. Interviews lasted between 30 and
90 min, with an average duration of 60 min. Most
interviews were audio recorded, unless participants re-
fused consent for recording (n = 3), and were transcribed
verbatim by the principal investigator if conducted in
English (n = 4) or by an interpreter using equivalent
translation from Karakalpak to English (n = 45), in order
to maintain the integrity and meaning of data. Of the
interviews transcribed by an interpreter, close to 50 % of
these were transcribed and translated by an independent
interpreter to maximise data validity. The three inter-
views that were not audio recorded were transcribed
using notes. Topic guides for follow-up interviews were
devised following review of initial interview transcripts
and identification of areas to further explore. Data col-
lection continued until new information was not being
generated, therefore evidencing data saturation [20, 21].
Data analysis
Data analysis began from the point of data collection
and followed an iterative process. Thinking and theoris-
ing began with interview notes followed by interview
transcripts, which were read and re-read, using coding
to identify emerging patterns and themes. Analysis was
performed manually, and drew upon principles of
grounded theory [22, 23], with constant comparison of
codes within and between cases to raise codes to a con-
ceptual level and to generate theory. Analytic memos
were used to track the development of analytic thought.
A coding framework was developed and then transcripts
were re-read to actively seek and explore discrepancies
from majority codes and categories, as well as contra-
dictory or unexpected findings, and to ensure findings
presented were a true reflection of participant accounts.
A second researcher reviewed the initial codes to en-
hance validity and minimise the effects of potential re-
searcher biases.
Results
52 interviews were conducted (35 MDR-TB patients, 12
health practitioners), including five follow-up interviews
(four patients, one health practitioner). Patient partici-
pants were aged from 16 to 69 years, 54 % were female
and 34 % had no prior treatment history. They com-
prised 15 ‘adherent’, 12 ‘partially adherent’, and eight LFT
patients (Table 1). Health practitioner participants
included five counsellors, five TB nurses, and two TB
doctors (Table 2). Twenty-four percent of the 46 patients
identified for recruitment did not participate for reasons
including: being untraceable, e.g. patients who were
abroad and therefore could not be invited to take part
(n = 6); unavailable during the study timeframe (n = 2);
fearing being brought back to treatment (one LFT
patient); or unknown (n = 2). The majority of those who
declined participation (n = 7) were LFT patients.
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Three main, interdependent themes were identified
through data analysis as underlying patients’ treatment-
taking experiences: 1. hope and better knowledge offer-
ing the potential to overcome non-adherence; 2. patient
autonomy and control optimising engagement with
treatment; and 3. perceptions of the body, self, treat-
ment, and disease on tolerance. These themes and the
framework comprising their sub-categories are described
below, and are also displayed in Table 3.
Where there is hope but limited knowledge
This theme explores the presence or absence of quality
TB knowledge, seen to influence the diagnostic and
treatment-taking process through impacting the views
Table 1 Patient participant characteristics
Patient code Gender Age group (years) Treatment-taking profile at time of interview Treatment history
P01 Female 20–29 Partially adherent New pt (no prior tx history)
P02 & P02 FU Female 20–29 LFT Extensive (DS to DR)
P03 & P03 FU Female 20–29 Partially adherent Extensive (DS to DR)
P04 Male 20–29 Adherent New pt (no prior tx history)
P05 Male 40–49 Adherent Tx after LFT from SCR
P06 Male 20–29 Partially adherent Previous incomplete DS tx
P07 Female 20–29 LFT Previous incomplete DS tx
P08 Male 50–59 Partially adherent Previous incomplete DS tx
P09 Female 20–29 Partially adherent Previous incomplete DS tx
P10 Male 20–29 Adherent New pt (no prior tx history)
P11 Female 20–29 Adherent Relapse
P12 Female 60–69 Adherent New pt (no prior tx history)
P13 Female 20–29 Adherent New pt (no prior tx history)
P14 Female 20–29 Partially adherent Relapse
P15 Male 30–39 Adherent New pt (no prior tx history)
P16 Male 20–29 Partially adherent New pt (no prior tx history)
P17 Male 40–49 Adherent Extensive (DS to DR)
P18 & P18 FU Female 20–29 Adherent Extensive (DS to DR)
P19 Male 16–20 Partially adherent New pt (no prior tx history)
P20 Male 20–29 Adherent Relapse
P21 Male 20–29 Adherent Relapse
P22 Male 20–29 Adherent New pt (no prior tx history)
P23 & P23 FU Male 16–20 Adherent New pt (no prior tx history)
P24 Female 30–39 LFT 1 previous course (failure after amplification)
P25 Female 20–29 LFT New pt (no prior tx history)
P26 Female 60–69 LFT 1 previous course (failure after amplification)
P27 Female 60–69 LFT 1 previous course
P28 Male 20–29 Partially adherent Relapse
P29 Male 30–39 LFT Relapse
P30 Female 30–39 Partially adherent Unknown
P31 Female 20–29 Partially adherent Unknown
P32 Male 30–39 LFT 2 previous courses
P33 Female 30–39 Partially adherent New pt (no prior tx history)
P34 Female 30–39 Adherent 1 previous course
P35 Female 30–39 Adherent 2 previous courses
FU follow-up interview, Tx treatment, Pt patient, LFT lost from treatment, DS drug sensitive, DR drug resistant, SCR short-course regimen (9 month MDR-TB
treatment regimen being piloted)
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and beliefs of patients on their need for treatment and
its perceived efficacy.
Limited TB knowledge and information
Most patients described limited TB knowledge and
understanding, as well as not being aware of the disease
prior to diagnosis, as relevant to adherence. Certain
primary health practitioners also described insufficient
TB knowledge among TB practitioners:
I had no idea about lungs. I have not even heard of it.
I learnt it when I got sick. P04
Several participants, patients and health practi-
tioners, described limited general health and TB
knowledge in the wider community. Knowledge that
did exist was described as being restricted to fear-
driven messages such as TB having no cure, fears of
infection, and TB developing as a perceived result of
a curse or jinx:
[Some] people in the community, the only thing they
know is that it will infect, that’s all, they don’t think
that it is curable. P03 (follow-up).
Locals say that it may be because of hex (jinx)…
Actually there is hex in medicine. It may affect you
lungs, head or eyes. Yes. Yes. It’s like a man loses his
aura. P26
The vast majority of patients described their MDR-TB
developing through factors relating to “cold”, in terms of
exposure to cold weather, wet ground, drinking cold water,
or getting a cold. Many patients also understood their dis-
ease as having developed through not having looked after
themselves, over-working, or through their immune sys-
tem weakening, for example due to inadequate diet, giving
birth, or physical trauma such as a car accident, which
could lead to self-blame. For some participants, medical
advice reportedly influenced these perceptions of disease
development. A minority of participants believed they
were infected with TB, or described their treatment his-
tory and drug resistance developing. Most patients
asserted that they were not infected.
It was cold in the house, I was feeling cold, couldn’t
look properly after myself. And mostly the field work…
I mean in 40 days after delivery women usually do not
go outside and it was not like this with me, I had to…
do the work… P03
They come and they say to put that on [mask]… I say
that I don’t transmit this disease. Because I was not
infected, I don’t know where I got it from. Otherwise
none of our generations have had this, neither my own
relatives nor here. P27
Medical education or advice was described by some
patients as restrictive for their health and wellbeing
Table 3 Coding framework after reduction of codes and categories
Theme Supporting treatment-taking Undermining treatment-taking
1. Hope and quality knowledge -Acceptance of diagnosis
-Perceived need for Tx
-Belief in Tx efficacy




-Support and encouragement (counsellor, peer,
family)




-Distrust of health services
-Myths and misinformation
-Negative peer influence
2. Patient autonomy and control -Ownership and self-responsibility
-Valuing health
-Strength of character, perseverance, motivation






-Stigma, shame, blame, isolation
-Social/financial responsibility










Tx treatment, HP health practitioner
Table 2 Health practitioner participant characteristics
HP position Number of participants Number of interviews
Counsellor 5 5
Nurse 5 6 (including 1 FU)
Doctor 2 2
HP health practitioner, FU follow-up interview
N.B. health practitioner positions have not been given for each participant
code to protect confidentiality of participants, due to the small number of
health practitioners for certain positions
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during and following treatment completion, including
activities that must be avoided after treatment comple-
tion to avoid disease relapse, which contributed to pa-
tients’ fears about the permanence of cure.
[Medical staff] they say to women not to give birth for
5 years. They say that during the delivery the lung
may dislocate, if there is a wound it may opened
again, and it may start bleeding. P03
They told us, they said “don’t lift anything more than
5 kg”, we submit to the discipline. P22
The majority of participants described TB transmis-
sion as occurring through materials or objects. Some
described it as being hereditary and only a few de-
scribed airborne transmission. Health practitioners
also mentioned the belief that TB is transmitted
through materials or objects existing among certain
TB health staff.
You should keep yourself clean. You should keep your
dishes separate… I have separate towel. P26
They [doctor] may be sitting with a TB patient in one
room, but he sits like separating his dishes and
avoiding touching that patient, but they are not afraid
of sitting in one room [without respirator]. HP 11
The information provided to and understood by pa-
tients during the diagnostic process often appeared to be
inadequate, with many patients describing their diagno-
sis having been explained as a spot or symptom in their
lung(s), without the opportunity to develop a better un-
derstanding. Patients reported receiving a brief explan-
ation of their disease by doctors, with counsellors being
relied upon for more expansive information.
I came and had X-ray they said “you have a spot in
your lung, you will go to TB2 [a hospital]”… They
didn’t say anything. P12
They said “your results are good but it is multi drug
resistant type” and I asked what it was, they said that
there was psychologist and we should see her. P18
During their diagnosis certain patients described being
in a state of shock in which it was difficult to process
the information given to them; this was echoed by most
health practitioners.
When they told me I didn’t understand. They told me
and I was so much in shock that I even don’t
remember what I was thinking about that time. P01
If it is the first time that they were told that they have
TB, even the health education part it’s too shocking…
It seems like they were under a shocking period to
accept the diagnosis even. HP 01
Several patients had taken an active approach to infor-
mation seeking relating to their disease and treatment,
involving using the internet, reading books, and asking
their peers or others. This was also described by some
health practitioners.
I started searching and I found that yes, this disease
really exists, that this disease is really curable, that
these drugs were not invented today nor yesterday,
that they are being used for a long time, they use these
drugs for more than 30–40 years. P01
Patient-to-patient information was seen to have more
credibility in terms of quality, trust, and belief in the in-
formation source. Those who had passed through treat-
ment themselves were perceived by patients as knowing
its reality and assumed more likely to be honest and reli-
able. However, there could be the risk of negative peer
influence, for example through LFT patients who ap-
peared well despite not completing their treatment
course.
If it is said by a person who takes the treatment it will
be accepted… Because he knows how you used to suffer
that’s why you believe him more than a healthy one.
P01
I know many patients who’d been given a “default”
outcome, but now they are good…some of them have
even started a job. P33
Quality information, knowledge, and belief supporting
adherence
Several participants mentioned the significance of dis-
ease knowledge and understanding for acceptance and
belief in treatment-taking. Some patients asserted that
belief in the treatment efficacy and its impact on cure
was the most important factor supporting the treatment-
taking process. Most patients saw belief as being integral
to the long and difficult treatment, giving strength to
overcome its challenges.
If they don’t have information, they won’t take
treatment. HP 07
If you believe in it then you will be cured. P21
Belief in treatment effect was reinforced through see-
ing symptoms and results improve, as well as seeing
other patients recover. This instilled a sense of motiv-
ation and determination.
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Day after day I take the drugs, months are passing, my
cultures are good, turning to negative, every 6 months
I am being x-rayed, everything is good. And because I
see such results I believe… I believed that I can be
cured with these drugs. P13
Doubt, myths, and adherence obstacles
Where patients doubted medical advice, including their
diagnosis, and did not ascribe value to MDR-TB treat-
ment, they appeared to be more vulnerable to misinfor-
mation, myths, and seeking alternative treatment. Doubt
and distrust were reportedly exacerbated through
changes in required treatment length and delays with ac-
curate diagnosis (including awaiting drug sensitivity test
results).
The idea that they were telling me a lie was inside of
me like a worm… I was like eating myself from inside
not believing it P01
They told me that it would be extended until
September and after that I started hating it completely
and I had missed about 20 days because of that. I lost
my inspiration to take the drugs. P19
Several patients and health practitioners described
myths, such as treatment being provided as part of a for-
eign drug experiment in which drug efficacy was not
known and was being tested. This was said to instil fear
in some patients and deter them from taking treatment,
and could be seen as demonstrative of patients’ distrust
in the health system.
In the streets people tell different information that
there are some trials are being held in our region. P01
Certain patients appeared to be conflicted about trust-
ing medical advice but also wanting to find an easier op-
tion or believing myths and misinformation. This led to
consideration of alternative treatment options, seen to
be less lengthy and arduous, and was also reportedly
fuelled through limited health knowledge and
understanding.
Unless the doctor delivers him the information fully
and explains in detail, that patient begins to look for
that information from other people. HP 11
So this time we also came home and I took dried
apricots. And I felt a bit better. After that I was living
normal, thinking that I was cured. P27
Some patients (in particular those LFT) did not believe
they currently or had ever had TB. This was especially
the case in asymptomatic patients, who expressed confu-
sion linked to the lack of pain receptors in the lung. Dis-
ease denial and disbelief were seen as negatively
impacting on treatment-taking.
I still don’t believe I have had TB… they said I got this
disease. We did not believe. It didn’t hurt anywhere.
P27 [LFT patient]
Patients’ understanding and belief also influenced
decision-making about when cure had been achieved.
Several patients believed they had been cured, for ex-
ample once their symptoms and/or results improved,
and therefore stopped treatment before completing the
full course, including many of the LFT participants.
I took the drugs for about 6–7 months, you know, then
my coughing stopped, I put on weight and then my
mother-in-law said “you look good, you don’t look like
you are sick, you don’t have to take the treatment”.
P03 follow up [history of previous LFT]
I said to myself I’m good, I won’t take the drugs for the
rest of the time because I feel better. All the results
were negative and good, and since I was also feeling
good the rest was depending on me. P24 [LFT]
Support and encouragement for treatment-taking
Support and encouragement from family, counsellors,
and peers were seen to help channel patients’ strength,
motivation, and determination in continuing with treat-
ment. Most patients cited their counsellor relationship
as supporting treatment-taking.
She really helped me much in continuing the
treatment. P01
I used to take treatment, take treatment well if I had a
support from someone. P02
Peer support was seen as providing a sense of shared
experience and solidarity. Certain patients described
forming their own peer support networks. For example,
one patient had connected with other young MDR-TB
patients, and they used social media daily to urge one
another to take their treatment.
I talk to them [other patients] through the Agent
(Russian social network), and you ask them at that
time like “have you taken your drugs”, you give advice
like “don’t miss”, then you meet often, that’s why we
are taking the drugs. P23 follow-up
The need for more education and information about
TB was highlighted by patients and health practitioners,
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at both the patient and community level. Suggestions
were made for the use of a variety of mechanisms for in-
formation sharing, including interactive and multi-media
based mediums such as film, radio, and television.
Put a screen here, and we all sit together there and
watch a short video, maybe for 10 min. And this video
should show the patient with this disease and his way
of treatment from the very beginning till the full
completion, but do it in a very nice way. So that
people who see it can believe in it. P13
Patients’ autonomy and control over their treatment
The second emerging theme explores positive engage-
ment with the treatment-taking process as reliant on pa-
tients’ sense of autonomy and ability to prioritise
treatment over and above conflicting demands on their
daily lives. This can be challenged by common beliefs,
myths, and stigma about TB, as well as authoritative
practitioner-patient relationships.
Social and personal spheres influencing patient autonomy
Treatment for MDR-TB was seen to have significant im-
pact on daily life, requiring sacrifices relating to educa-
tion, employment, and duties and responsibilities such
as housework, as well as having social implications.
Many patients said that they had worked prior to start-
ing treatment, but were no longer able to do so. Patients
described feeling so weak after taking the drugs that all
they could do was to lie down; they couldn’t concentrate
on studying and felt unable to care for their children or
perform duties around the home.
I used to think of everything, like: “I am not able to do
anything anymore”. I used to cry because of that. I was
also thinking that I couldn’t look after my children.
When I go home… I couldn’t do anything at home,
couldn’t do anything. P11
Single patients described feeling unable to marry until
they had finished treatment, and several younger pa-
tients felt isolated from their friends and that they were
missing out on activities that their peers were taking part
in, such as attending events.
I was young at that time, around 16. Young heart, you
know. And 2 years, oh, wow… you have to be
separated from your friends and so on for 2 years. So I
thought about that, about 2 years of separation. P19
Significant stigma was described by many participants,
both perceived and enacted. Patients felt ashamed, as
though people blamed them and looked at them differ-
ently because of their disease. They also described
feeling ostracised and asserted wanting to hide their dis-
ease status.
I felt like healthy people were looking at me with
disgust. P13
Many patients felt defined by their disease, their lives
consumed by the routine of treatment-taking and side
effects, separating them from a sense of normality and
society. Some expressed a desire to feel equal, with a life
beyond treatment and disease.
That constant condition of half a man, I used to feel
like a half man. P01
Actually there is nothing worse than staying at home
and just take the drugs. I wish to complete this
treatment, get cured, work like others, get salary, and
attend celebrations and other events (crying). P34
Gender and societal status were important determi-
nants of patients’ autonomy and their ability to prioritise
treatment. Most female patients who were, or had been,
married described the implications of their role as
daughter-in-law for treatment-taking. Many were ex-
pected to serve their husband’s family following mar-
riage, with their position resulting in a lack of control
over their health or lives. Some had severe difficulties
continuing with treatment, including who described be-
ing seen as useless because side effects prevented their
ability to perform household duties. Some patients were
therefore unable to continue their treatment and only
able to resume following divorce or leaving their hus-
band’s family home, which was described as very difficult
in the social context. Some female patients suggested
that it could be better for daughter-in-law patients in
this position to take treatment in hospital.
While taking the treatment, my husband’s house were
against… [they] wouldn’t let me take treatment… I
took the drugs for about 6 months and then left, being
a defaulter… What they say is: “we need someone who
will serve us…” P03
There were some counter examples, with some married
women asserting that they received support from their
husband and in-laws. These patients seemed to live in sep-
arate homes from their in-laws, and in certain cases their
family members had received treatment education
through engagement with counsellors, described as par-
ticularly helpful in achieving their husband’s support.
Many male patients expressed frustration at not being
able to work while on treatment, some highlighted their
responsibility to provide for their family, with one LFT
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patient explaining that this was why he felt no choice
but to stop treatment early. Socio-economic barriers to
treatment-taking were reiterated by health practitioner
participants.
Due to my family reasons I couldn’t… I had to stop the
treatment. Because there was no other source of
income. P32 (LFT)
Age affected treatment-taking experience. Younger pa-
tients were perceived as being able to recover more
quickly and better tolerate the drugs, whereas older pa-
tients expressed fatigue and found drug tolerance diffi-
cult, particularly if there were co-morbidities. Some
older patients viewed themselves as having limited time
left alive, with 2 years of treatment therefore being a sig-
nificant burden. For certain younger patients, however,
2 years seemed a comparatively short period.
Recovery will be quick… my organism is young. P19
Sometimes I don’t feel like taking that drug, you know.
When I don’t feel like taking the drug, I say “I’ll stop
from today on, I am 70 years old, that’s it, if I die it’s
fine”. P12
Patients who described valuing their health and who were
able to prioritise it above other demands demonstrated
ownership, autonomy, and self-responsibility for the
treatment-taking process, which drove them to persevere.
These patients accounted strength of character and motiv-
ation as relevant to treatment-taking, alongside having aspi-
rations and plans for their lives post-treatment, for example
having a family, getting married, working, or studying.
Strength of character was also acknowledged by health
practitioner participants as important in overcoming chal-
lenges with treatment; some associated this with family
background and education level.
I have my natural strength… I force myself every day,
otherwise I won’t be able to take them. I can’t take
them if I don’t push myself to it. P27
Every man decides for himself… I need my health for
my own sake. Because I need it for myself I have
decided it. P21
There are patients who become a defaulter because of
social problems they have but there are also patients
with social problems who are still trying to find a way
out and to continue with the treatment to the end.
HP 09
The practitioner-patient relationship undermining patient
authority
The power inherent in the practitioner-patient relation-
ship was alluded to, with conflicting views about health
practitioner communication style and approach. Certain
patients described their relationship with doctors and
nurses as positive, involving help and encouragement.
Most of these patients seemed to be adherent, with some
saying doctors praised them for their treatment-taking.
Other patients highlighted the distrust that could exist
within the relationship, and expressed being abused and
threatened by doctors, and feeling angry about or afraid
of practitioner attitudes. Some doctors were seen as just
inspecting their treatment-taking, rather than perform-
ing full medical examinations and providing explana-
tions. Patients described doctors begging them to take
their drugs and feeling annoyed with them if they didn’t.
I used to have fear of their attitude. P13
The doctors also get angry and they begged saying
“take your drugs, take your drugs”… the doctors are
also fed up with me. P14
Health practitioner participants highlighted the need
for improved staff-patient communication, trust, mutual
commitment, and respect. Practitioners explained that
the staff-patient relationship impacted treatment adher-
ence. A relationship that centred on blame and inspec-
tion of drug taking was seen to hinder patients’ ability to
share adherence challenges. Begging patients to continue
with treatment was seen to undermine their autonomy
and self-responsibility for treatment-taking.
The communication level should be very improved,
patients should be seen as people… he should be a
participator in his treatment… give space for patient
to decide in his situation rather than one sided
communication. HP 01
Side effects from drugs and solutions for tolerance
How patients experience and perceive the impact of
TB and treatment on their body presents the third
and final theme. Such perceptions influence treatment
tolerance and therefore the ability to continue to take
treatment.
All patients described experiencing side effects at
some point during treatment. A range of physical side
effects were outlined, with many patients experiencing
nausea and vomiting, loss of appetite, weakness, head-
aches, joint swelling, and pain, particularly in the legs.
Patients stated experiencing dizziness and feeling drunk,
changes in their appearance through skin discolouration,
blurred vision, burning, itching, and diarrhoea. Psycho-
logical side effects were also described, including low
mood, nervousness, loss of memory, and thinking nega-
tive, dark thoughts.
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I used to vomit until the evening… I used to feel dizzy,
was almost about to fall down, felt so weak.
Shivering… my hands and legs were shivering after
vomiting. P25
I take the drugs. Then I am knocked down… mouth
full of saliva, feel drunk, don’t have any power to do
anything. P27
Many patients viewed side effects as being worse at the
beginning of treatment, reportedly becoming more toler-
able after 2 to 3 months, when the body was said to adjust
to the drugs. However, there were two exceptions to this,
where patients’ side effects were considered to become
worse over time, as their body started refusing the drugs.
In comparison to the initial stage of my treatment the
difficulties I have now are much easier. I don’t suffer
that much… I think my body got used to the drugs.
P07
Actually after the sixth…after the 7th or 8th month of
treatment I realised that my body started refusing. P33
Some patients perceived treatment as poisoning other
parts of the body, helping the lungs at the expense of
the liver, kidneys, and stomach, for example. Some felt
that their body was being ruined by drug toxicity, feeling
unable to continue with treatment as a result, and fear-
ing death from liver failure.
If you lose liver then you will die soon. If you lose lung
you will live a bit longer… I said I wouldn’t take them
anymore. I will spoil my liver, my liver will be
destroyed. P27
It’s like it has made all my bodies not function… all is
ruined. P29
Now I vomit because I am poisoned with the drugs.
P33
Certain patients expressed a sense of treatment fatigue,
feeling that they had had enough of the burden of drug-
taking and experiencing side effects each day. This was
seen to undermine their motivation to continue with
treatment and caused some patients to want a break. It
was given as the reason for some stopping treatment or
missing doses.
I am fed up and refused completely. I stopped for
2 months. P18
Individuals were seen as tolerating drug side effects
differently, with some patients not feeling able to
tolerate the drugs at all. Certain patients found that tol-
erance became more difficult as the week progressed,
with a perceived build-up effect, highlighting the import-
ance of a rest day from treatment.
When I took those drugs I suffered. I had been
suffering for 2 years, vomiting, I couldn’t tolerate at
all. I used to vomit for 2 years, it didn’t stop. P25
We don’t take the tablet on Sundays… on those days I
feel myself good like old times. P35
Medical side-effect management had mixed reviews
from patients and health practitioners. Some found
that anti-side-effect drugs helped, others experienced
no difference, and one patient felt worse with anti-
emetic drugs. Several patients described feeling reluc-
tant to try anti-side-effect drugs due to an aversion to
increasing their pill intake. Health practitioners also
described some patients hiding side effects to avoid
increased pill burden. This factor limited the impact
of medical support for side-effect tolerance and there-
fore adherence.
If I take the anti-vomiting drug my drugs neither digest
nor come out from my mouth. And I feel very bad. Bet-
ter not to take anti-vomiting drug but try to keep the
drugs for at least half an hour or an hour or so. P33
A psychological ‘sphere’ to drug tolerance was de-
scribed by many patients and health practitioners, with
mood and mind set reportedly influencing the extent to
which side effects were felt and experienced. This links
to the concept of patients’ views around self, health, and
the effect of the drugs. Focusing on positives was seen to
lessen side effects and improve tolerance; whereas being
around other patients discussing side effects and focus-
ing on negatives was said to make treatment-taking and
tolerance more difficult.
If you suffer and you think of something bad you will
not be able to take the drugs, it’ll be even worse. And if
you are joyful and don’t think of anything bad then
the drugs will not… [affect] you much. P11
These drugs also can work depending on your mood. If
a man is in a good mood then these drugs can be
absorbed well and there might be no side effects. That’s
why after you take the drugs you should….[think]
positively P21
When people have some hope, when people see life
very happy they tolerate more or less better than
people who are very depressed. HP 08
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Some patients described using visualisation techniques
to build a positive mind set, helping with drug tolerance.
These included visualising the drugs helping the body,
strengthening it and providing a cure, as well as tactics
such as imagining the drugs were grapes or sweets. Con-
versely, some patients described developing a negative
association with drugs, which led to them feeling nause-
ous at the sight or even thought of them, including
drugs not related to MDR-TB.
I used to vomit when I saw them. P31
You try to distract yourself a bit like you are taking
only grapes. P33
Distractions from treatment were referred to as help-
ing with drug tolerance and treatment-taking, which
supports the notion of visualisation as a useful tech-
nique. Patients described activities such as walking out-
side, talking to friends or family, watching television,
listening to music, or keeping busy in some way. Having
distractions like these were said to be important, helping
the days and treatment-taking pass more easily and im-
proving mood.
I come home after taking drugs and then go for a walk.
That time you can forget, distract yourself… It helps to
be distracted from the drugs. P19
If you walk around or chat with someone, if you talk
about something good to someone or listen to music
then I think the drugs will digest well. P21
Patients described different tactics to help them digest
and tolerate the drugs, which varied for each individual.
The coping mechanisms described included splitting
doses or taking the drugs in one go, taking them with
yoghurt or watermelon, lying down for 2–3 h after tak-
ing them, and performing mindfulness and meditation
exercises with counsellor support. Food was mentioned
as being important for drug tolerance, helping with tak-
ing the drugs and masking their taste, as well as report-
edly improving side effects. Certain patients also
highlighted the importance of a peaceful environment,
with quarrelling, nervousness, and anger seen as under-
mining motivation for drug-taking, as well as worsening
drug tolerance and disease progression.
They say if a man is nervous then the vessels in lungs
would be swollen and explode. P18
Discussion
We found several factors that influenced the ability to
adhere to MDR-TB treatment. Hope and high quality
knowledge can support adherence; autonomy and con-
trol can enable optimal engagement with treatment-
taking; and perceptions of the body, self, treatment, and
disease can influence drug tolerance. As far as we are
aware, the influence of patient autonomy and control on
TB treatment-taking has not previously been described.
In particular, we found that the autonomy of some mar-
ried women around treatment-taking was undermined
through their societal position as daughter-in-law, com-
promising their ability to adhere to treatment. We also
found that patients’ engagement with treatment and ad-
herence could be undermined through hierarchical
practitioner-patient relationships that displaced author-
ity, ownership, and responsibility from the patient.
The importance of patient knowledge and information
for adherence and retention in treatment has been docu-
mented [24]. Lack of information is associated with LFT
[25] and poor treatment outcomes [26], and patient edu-
cation is said to be one of the most effective interven-
tions for reducing LFT in DR-TB [5]. However, our
finding that patients had insufficient knowledge despite
being in a programme that provided pre-treatment infor-
mation and on-going patient counselling is noteworthy,
particularly as some of these patients had been on treat-
ment for considerable periods. Our study adds import-
ant additional insight into the role of mind set and
visualisation for drug tolerance, building on previous lit-
erature on the influence of drug side effects on adher-
ence to MDR-TB treatment [12, 15, 24, 27, 28].
In the first theme that we identified, the presence of
TB knowledge was seen to increase the likelihood of
continuous engagement with treatment through influ-
ences on motivation, belief in the need for treatment
and its efficacy, and hope for cure. Several patients, par-
ticularly those partially adherent or LFT, appeared to
lack understanding about the implications of missing
doses and the need to complete the full course of treat-
ment. Certain patients defined themselves as cured once
their symptoms improved or their culture results be-
came negative, and thus stopped treatment before com-
pleting the full course. Several LFT patients did not
believe they had TB despite receiving pre-treatment in-
formation and counselling during treatment. Doubt and
distrust of the information received was expressed by
several patients, exacerbated through changes in culture
results and drug sensitivity test analyses. Some patients
also appeared to be vulnerable to misinformation and
myths, including those relating to alternative treatment
options that were deemed to be less arduous and
lengthy. Other studies have found that perceptions
around cure and belief can cause adherence difficulties,
with patients deciding they no longer need treatment
once symptoms improve with treatment for MDR-TB [8]
and drug-sensitive TB [3]. MDR-TB patients in other
Horter et al. BMC Infectious Diseases  (2016) 16:362 Page 11 of 15
settings have been found to fear treatment as harmful
and ineffective [8], and to not understand the implica-
tions of missing doses [7].
The active approach to information seeking expressed
by several patients in our study could indicate insuffi-
cient provision of information from official sources
within the programme. The patients who expressed ac-
tively seeking further information about their disease
and treatment were all female, and most were young.
Several participants expressed the need for more patient
education, available in different formats and at different
stages throughout the treatment course. This confirms
the need to capitalise on the existing desire of patients
for knowledge. Using mechanisms that enhance trust,
such as peer-to-peer information could increase the like-
lihood of patients believing in the treatment. Certain pa-
tients also demonstrated a proactive approach to
motivation through peer support by self-forming patient
support networks. The patients who described valuing
peer support were mostly young (under 30 years), male
and female, and the majority were adherent. Counsellor
and peer support was key to instilling hope for patients,
similar to research showing that counsellor support is
crucial for increasing patients’ belief in cure [27].
In the second major theme we identified, patients’ au-
tonomy and engagement around their treatment-taking
was found to be influenced by social discourse on TB
and authoritative relationships in their family, social, and
medical lives. These affected patients’ ability to prioritise
treatment over conflicting demands, as well as their
sense of responsibility and ownership. Patients with re-
silience, intrinsic motivation, and who valued their
health were said by health practitioners to be better able
to continue with treatment and overcome its challenges.
Treatment for many patients with MDR-TB has an im-
pact on their sense of self and their lives through hinder-
ing their ability to work, study, and perform normal
activities [27, 28]. In our study, patients’ limited control
and autonomy over their lives and TB care influenced
their ability to adhere to treatment. Certain female pa-
tients asserted the challenges they faced trying to bal-
ance the requirements of their role as daughter-in-law
with those of treatment. Married female patients whose
families did not support treatment often found them-
selves unable to continue, highlighting the need for in-
volvement of family members where possible, and the
availability of other options such as hospital-based care
where this is not feasible. Patients reported that their so-
cial and financial responsibilities, including the need to
work and earn money, could create barriers to
treatment-taking. This was particularly mentioned by
male patients, who had a responsibility to provide for
their families, and some of them felt unable to continue
with treatment as a result. These socio-economic
barriers to treatment continuation have been noted pre-
viously as being associated with LFT or poor adherence
[4, 7, 10].
The power inherent in the practitioner-patient rela-
tionship could shape patients’ interactions with their
treatment. A “good patient, bad patient” dynamic was
reflected, with some patients who adhered well reporting
praise from doctors and nurses, whereas other patients
felt blamed, shouted at, and inspected. This style of
communication was seen to deter patients from feeling
able to raise and discuss the challenges they were facing,
and undermined their control and ownership over their
treatment. This in turn led in some cases to a rebellious
response from patients with regard to taking treatment,
a response which has been explored further in Foucault’s
work on the power dynamic and hierarchy within
practitioner-patient relationships [29]. Health practi-
tioner training is needed to improve practitioner-patient
communication, collaboration, mutual commitment, and
decision-making. The importance of adequate heath
practitioner training [7] and an approach that enhances
patient ownership and involvement [24] are clear.
The third theme we found highlights the relevance of
disease embodiment and the ways in which a person
perceives and interacts with treatment both physically
and psycho-socially. The fact that all patients asserted
experiencing side effects at some point in their treat-
ment demonstrates the difficulties associated with taking
such toxic drugs. Several patients described perceptions
that the drugs were poisoning them, for example curing
their lungs at the expense of other organs such as their
liver. Other studies have reported patients’ experiences
with side effects [12, 27, 28], with one qualitative study
describing the negative impact of adverse drug effects on
adherence [24]. While other studies have found the
number of drugs as increasing risk of LFT [15], our find-
ings provide insight into the ways in which a patient’s
outlook can influence MDR-TB drug tolerance.
Patients felt better able to tolerate the treatment if
they had a more positive view of the drugs. Using tech-
niques such as visualisation and distractions from treat-
ment reportedly eased drug tolerance and therefore
promoted drug-taking. Patients reported feeling drug
side effects more acutely if they focused on them, or
were around other patients suffering from them. At the
same time, reinforcement of health care workers’ skills
to support patients with long-term treatment and drug
intake could help patients to believe in the chance of
achieving a successful treatment outcome, which in turn
could motivate good adherence to treatment.
Limitations
While identification of participants for potential recruit-
ment in the study followed several steps, the role of
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health practitioners in approaching potential partici-
pants, informing them about the study and requesting
their voluntary participation may have influenced re-
cruitment in its reliance on their relationship with these
individuals. However, as these health practitioners were
predominantly counsellors who had supportive relation-
ships with selected patients this should not have nega-
tively influenced recruitment and may have encouraged
participant openness. LFT participants took longer to
identify and required adaptation of the recruitment ap-
proach to include direct introduction of the study by the
Principal Investigator (PI). As we were unable to include
patients who were abroad, this hindered exploration of
their experiences with stopping treatment early. How-
ever, the financial and social responsibilities that can in-
fluence patients’ adherence have been portrayed, which
may also have applied to these patients (some of whom
likely migrated for employment reasons).
It is acknowledged that participants could have shared
a narrative that portrayed the account they thought the
researcher wanted to hear; for example, health practi-
tioner criticism was more directly described by practi-
tioner participants than by patients, which could
indicate an association of the researcher with the health
programme. However, the fact that the researcher was
not from the programme potentially countered this ef-
fect; participants were generally open regarding their ex-
periences, views, and struggles. The role of the PI in
shaping the data must also be acknowledged and
reflected upon. While steps were taken to reduce re-
searcher bias during the data collection and analysis
process, for example through the review of coding and
analysis by a second researcher, the PI’s involvement in
designing the study, and in data collection and analysis,
is likely to have influenced the study findings. As is to be
expected in qualitative research, the concepts arising in
this study may be generalisable to the larger population
treated in the programme, but these may not be found
in other contexts or in dissimilar settings.
Conclusions
Patients experienced a variety of challenges throughout
their treatment, reinforcing the need for an individua-
lised and holistic approach to adherence support. This
study suggests that quality knowledge, hope and belief,
and patient autonomy and control can support MDR-TB
treatment-taking; and that there is a psychological
sphere to treatment which influences drug tolerance.
Improving patients’ knowledge and understanding re-
lating to TB treatment and disease could help them have
the belief, hope, determination, and motivation to
complete treatment. A space within which patients have
a sense of authority and autonomy over their treatment
must be created, for example through enhanced
practitioner-patient communication and minimising so-
cial barriers, so that patients are active participants in
their care and feel ownership and responsibility for their
treatment. Finally, while adverse drug effects are experi-
enced by the majority of patients, mechanisms have been
found to help patients cope with and overcome difficul-
ties with them and should be implemented as part of ad-
herence strategies, such as the employment of
visualisation techniques and distractions from treatment,
which were found to ease the burden of side effects in
this study.
As we move towards the introduction of new drugs
and treatment regimens for MDR-TB, the potential im-
pact on adherence and how best patients can be sup-
ported should be considered as integral components of
future studies and programmes.




Increase the availability of
information to patients at different
stages of the treatment course
(beyond point of diagnosis)
Patient information should also




Expand peer support services for
MDR-TB patients
Counsellor support should be made
available to patients, tailored to meet
individual psychosocial support
needs, including the option for family
engagement and to support
gendered experiences which can
influence treatment-taking
Patient autonomy and control
over treatment-taking
Practitioner-patient relationships
should facilitate dialogue so patients
feel able to discuss any challenges,
concerns and queries they might
have
Offer practitioner training and
engagement on communication
Offer support for practitioners who
may face challenges with the burden
of workload and responsibility for
achieving successful patient
outcomes
Patient perceptions of the self,
body, treatment and disease on
tolerance – drug side effects
Offer support for patients around
mind set and treatment-taking – as
focusing on positives and seeing
treatment as strength-giving was
found to offer the potential to ease
difficult drug side effects
Employment of visualisation
techniques and distractions from
treatment could also support patients
with drug tolerance
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